Cargando…
Polycyclic aromatic hydrocarbon-DNA adducts and the CYP1A1 restriction fragment length polymorphism.
Human cancer risk assessment at a genetic level involves the investigation of carcinogen metabolism and DNA adduct formation. Wide interindividual differences in metabolism result in different DNA adduct levels. For this and other reasons, many laboratories have considered DNA adducts to be a measur...
Autores principales: | Shields, P G, Sugimura, H, Caporaso, N E, Petruzzelli, S F, Bowman, E D, Trump, B F, Weston, A, Harris, C C |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
1992
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1519599/ https://www.ncbi.nlm.nih.gov/pubmed/1362539 |
Ejemplares similares
-
Detection of polycyclic aromatic hydrocarbon-DNA adducts in human lung.
por: Weston, A, et al.
Publicado: (1993) -
DNA adducts and carcinogenicity of nitro-polycyclic aromatic hydrocarbons.
por: Fu, P P, et al.
Publicado: (1994) -
Polycyclic aromatic hydrocarbons and PAH-related DNA adducts
por: Ewa, Błaszczyk, et al.
Publicado: (2016) -
DNA adducts as a measure of lung cancer risk in humans exposed to polycyclic aromatic hydrocarbons.
por: Kriek, E, et al.
Publicado: (1993) -
Survival of polycyclic aromatic hydrocarbon knockout fragments in the interstellar medium
por: Gatchell, Michael, et al.
Publicado: (2021)